Need Tally
for Clients?

Contact Us! Here

  Tally Auditor

License (Renewal)
  Tally Gold

License Renewal

  Tally Silver

License Renewal
  Tally Silver

New Licence
  Tally Gold

New Licence
 
Open DEMAT Account with in 24 Hrs and start investing now!
Top Headlines »
Open DEMAT Account in 24 hrs
 7 mistakes to avoid while filing Income Tax Return online ITR filing
 How to file income tax return using Form 16? A step by step guide
 New Tax Regime rule change: Marginal income over Rs 7 lakh may become tax-free; 5 points
 PAN-Aadhaar link to ITR filing: 5 money tasks to complete in March 2023
 How new tax regime may impact homebuyers in FY24?
 ​Income-tax (3rd Amendment) Rules, 2023
 Income Tax Filing: 6 key money matters that beckon your attention this month
 Back New income tax regime: How to save tax if annual income is above ₹7 lakh?
 Income tax return (ITR) forms for FY 2022-23 (AY 2023-24) released by CBDT

`Extend R&D tax benefits to pharma cos'
December, 21st 2006

The Associated Chambers of Commerce and Industry of India (Assocham) has called on the Government to extend the tax benefits available for R&D to pharmaceutical companies by 10 years. The provisions of Section 35 (2AB) of the I-T Act are to expire on March 31, 2007.

Assocham says that without tax exemption, the domestic pharmaceutical industry would have to incur huge expenditure, and that an extension till 2017 would help the industry in long-term planning and research to face competition.

The chamber has written to the Ministries of Chemicals and Fertilisers and Finance for the same, pointing out that while the R&D spend by major Indian companies is only about 5 per cent of their turnover, globally large pharma companies spend 15 per cent on R&D.

R&D spend

According to Assocham, R&D spend has grown at CAGR of 38 per cent between 2001-2006. Additionally, the chamber has also asked for exemption for services provided and availed in R&D, import of capital goods for R&D and expenditure on clinical trials, under the above Act.

It has also urged the Government to exempt import duty on clinical trial samples and authorise the Drug Controller General of India to decide who qualifies. The industry body would also like clinical trials conducted by Indian companies outside the country to enjoy the same tax benefits that they do when they conduct them within the country.

Home | About Us | Terms and Conditions | Contact Us
Copyright 2023 CAinINDIA All Right Reserved.
Designed and Developed by Ritz Consulting